TriSalus Life Sciences, Inc. TLSI Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $44.88M+39.6% | $45.15M+53.4% | $40.21M+49.5% | $35.99M+45.5% | $32.14M+46.2% | ||
| $6.7M+44.8% | $6.97M+69.8% | $6.42M+85.0% | $5.52M+80.6% | $4.63M+58.8% | ||
| $38.18M+38.8% | $38.19M+50.8% | $33.79M+44.3% | $30.47M+40.6% | $27.51M+44.3% | ||
| 85.1%-0.5pp | 84.6%-1.5pp | 84%-3.1pp | 84.7%-3.0pp | 85.6%-1.1pp | ||
| $14.89M+0.1% | $14.69M-16.9% | $15.08M-33.0% | $14.12M-49.2% | $14.87M-50.5% | ||
| $29.39M+13.5% | $28.71M+11.1% | $27.75M+13.6% | $27.05M+17.7% | $25.89M+26.4% | ||
| $21.94M+18.0% | $21.73M+21.0% | $22.22M+15.0% | $20.29M-14.1% | $18.59M-24.3% | ||
| -$28.03M+11.9% | -$26.95M+25.5% | -$31.26M+27.0% | -$30.98M+41.2% | -$31.82M+43.1% | ||
| -62.4%+36.6pp | -59.7%+63.2pp | -77.7%+81.5pp | -86.1%+127pp | -99%+156pp | ||
| $5.77M+34.3% | $5.54M+79.4% | $5.16M+155% | $4.84M+446% | $4.3M+30,586% | ||
| -$281K+31.5% | -$456K-46.2% | -$487K+8.5% | -$406K+23.7% | -$410K-3,870% | ||
| -$27.31M-0.4% | -$39.22M-30.6% | -$39.58M+28.8% | -$31.17M+42.9% | -$27.21M+57.6% | ||
| $6K— | $7K— | —— | —— | —— | ||
| -$27.31M-0.4% | -$39.23M-30.6% | -$39.58M+28.8% | -$31.17M+42.9% | -$27.21M+57.6% | ||
| -60.9%+23.8pp | -86.9%+15.2pp | -98.4%+108pp | -86.6%+134pp | -84.7%+208pp | ||
| $714K-77.0% | $1.43M-55.3% | $2.21M-31.1% | $3.01M+5.3% | $3.1M+50.5% | ||
| -$1.32-17.9% | -$1.74-30.8% | -$2.02-2.0% | -$1.18+41.0% | -$1.12+97.0% | ||
| -$1.32-17.9% | -$1.74-30.8% | -$2.02-2.0% | -$1.18+41.0% | -$1.12+97.0% | ||
| 166.2M+59.4% | 142.4M+43.7% | 129.8M+56.2% | 113.3M+62.3% | 104.3M+125% | ||
| 165.4M+58.6% | 142.4M+43.7% | 129.8M+56.2% | 113.3M+62.3% | 104.3M+125% | ||
| -$5.48M+64.0% | $2.74M+123% | -$2.4M— | -$2.24M— | -$15.23M— | ||
| $638K— | -$4.1M— | -$4.68M— | —— | —— | ||
| $638K+112% | -$4.1M-94.4% | -$4.68M+64.1% | $3.22M+115% | -$5.46M+49.2% | ||
| -$281K+31.5% | -$456K-46.2% | -$487K+8.5% | -$406K+23.7% | -$410K+20.1% | ||
| $44.88M+39.6% | $45.15M+53.4% | $40.21M+49.5% | $35.99M+45.5% | $32.14M+46.2% | ||
| -$28.03M+11.9% | -$26.95M+25.5% | -$31.26M+27.0% | -$30.98M+41.2% | -$31.82M+43.1% | ||
| -$27.44M+11.7% | -$26.32M+25.7% | -$30.56M+27.4% | -$30.27M+41.8% | -$31.08M+43.8% | ||
| -$27.44M+11.7% | -$26.32M+25.7% | -$30.56M+27.4% | -$30.27M+41.8% | -$31.08M+43.8% | ||
| -61.1%+35.6pp | -58.3%+62.1pp | -76%+80.5pp | -84.1%+126pp | -96.7%+155pp | ||
| -$28.03M+11.9% | -$26.95M+25.5% | -$31.26M+27.0% | -$30.98M+41.2% | -$31.82M+43.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is TriSalus Life Sciences, Inc.'s revenue?
- TriSalus Life Sciences, Inc. (TLSI) generated $44.9M in revenue over the trailing twelve months, up 39.6% year over year.
- Is TriSalus Life Sciences, Inc. profitable?
- TriSalus Life Sciences, Inc. is not currently profitable: it reported a net loss of $27.3M over the trailing twelve months, a -60.9% net margin.
- What are TriSalus Life Sciences, Inc.'s profit margins?
- Gross margin is 85.1% and operating margin is -62.4%, with a -60.9% net margin.
- What is TriSalus Life Sciences, Inc.'s earnings per share?
- TriSalus Life Sciences, Inc.'s diluted EPS over the trailing twelve months is $-1.32.
- Where does TriSalus Life Sciences, Inc.'s income statement data come from?
- Every line is extracted from TriSalus Life Sciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
